RESEARCH > Research Projects > Catalyst Projects

Catalyst Projects

Anti-DEC205 priming in heterologous prime-boost with OVs for sarcoma

 

Dr. Jean-Simon Diallo, The Ottawa Hospital Research Institute, The Ottawa Hospital
Approved April 23, 2018 | Project value $200,000 | 1 partner | $100,000 from BioCanRx

 

Eligible cancers: Sarcoma
Keywords: anti-DEC205 priming, oncolytic viruses, combination therapy

 

 
 

 
 

Ground-breaking immunotherapy to prevent acute lymphoblastic leukemia relapse: dosage and therapeutic settings of plasmacytoid dendritic cell infusions

 

Dr. Michel Duval, CHU St-Justine
Approved April 23, 2018 | Project value $544,875 | 1 partner | $214,875 from BioCanRx

 

Eligible cancers: Acute Lymphoblastic Leukemia (ALL)
Keywords: plasmacytoid dendritic cells, hematopoietic stem cell transplantation (HSCT), pDC adoptive transfers, NK cell enhancement

 

 
 

 
 

Improving adoptive cell transfer immunotherapy with clinical-grade cell sorting of tumor-reactive T cells infiltrating solid tumors

 

Dr. Simon Turcotte, Centre hospitalier de l’Université de Montréal (CHUM)
Approved April 23, 2018 | Project value $404,500 | 8 partners | $200,000 from BioCanRx

 

Eligible cancers: Melanoma and colorectal cancer
Keywords: adoptive cell transfer immunotherapy, PD1-expressing tumour-infiltrating lymphocytes, cell sorting

 

 
 

 
 

IN VIVO GENOME-WIDE CRISPR/CAS9 SCREEN TO IDENTIFY GENES THAT LIMIT CURATIVE CHECKPOINT BLOCKADE IMMUNOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER

 

Dr. Karen Mossman, McMaster University
Approved January 31, 2018 | Project value $198,650 | 2 partners | $98,650 from BioCanRx

 

Eligible cancers: Triple negative breast cancer
Keywords: CRISPR, checkpoint blockades

 

 
 

 
 

TARGETING THE RELAXIN AUTOCRINE LOOP IN HIGH GRADE SEROUS OVARIAN CANCER USING RLN2 NEUTRALIZING MONOCLONAL ANTIBODIES AS A THERAPEUTIC STRATEGY

 

Dr. Robert Rottapel, Princess Margaret Cancer Centre, University Health Network
Approved July 6, 2017 | Project value $424,500 | 3 partners | $199,500 from BioCanRx

 

Eligible cancers: ovarian cancer
Keywords: monoclonal antibodies (mAbs), RNL2 neturalizing antibodies, Relaxin Receptor

 

 
 

 
 

SCALABLE VECTOR MANUFACTURING ENHANCEMENT USING VIRAL SENSITIZERS

 

Dr. Jean-Simon Diallo, The Ottawa Hospital Research Institute, University of Ottawa
Approved April 1, 2017 | Project value $474,800 | 3 partners | $200,000 from BioCanRx

 

Eligible cancers: oncolytic viruses & gene therapy vectors
Keywords: Measles virus (MV), Maraba MG-1, Lentivirus (LV) oncolytic virus, adoptive cell therapy, CAR T, manufacturing gene therapy vectors, viral sensitizer

 

 
 

 
 

EVALUATION OF FGL2 AS A THERAPEUTIC TARGET IN OVARIAN CANCER

 

Dr. Barbara Vanderhyden, The Ottawa Hospital Research Institute, University of Ottawa
Approved April 28, 2017 | Project value $157,996 | 4 partners | $78,996 from BioCanRx

 

Eligible cancers: ovarian cancer (high-grade serous ovarian cancer)
Keywords: Fibrinogen-like 2 (FGL2), combination, immunotherapeutic, regulatory Tcells (Tregs), antibodies, Maraba MG1.

 

 
 

 
 

Optimizing a personalized infected cell vaccine (ICV) for peritoneal carcinomatosis

 

Dr. Auer, Rebecca, The Ottawa Hospital Research Institute, University of Ottawa
Approved October 14, 2016 | Project value $406,730 | 6 partners | $220,230 from BioCanRx

 

Eligible cancers: abdominal cancers (peritoneal carcinomatosis)
Keywords: oncolytic virus, Maraba oncolytic virus, interleukin 12, infected cell vaccine (ICV)

 

 
 

 
 

Validation and manufacturing of anti-BCMA-TACT cells for the treatment of multiple myeloma

 

Dr. Jean-Sebastien Delisle, Hôpital Maisonneuve-Rosemont, Université de Montreal
Approved October 14, 2016 | Project value $448,478 | 3 partners | $200,000 from BioCanRx

 

Eligible cancers: multiple myeloma (MM)
Keywords: engineered T cells, TACT, BCMA TAC lentivirus

 

 
 

 
 

New generation chimeric antigen receptors for improved adoptive T cell therapy for cancer

 

Dr. Naoto Hirano, The Princess Margaret Cancer Centre
Approved January 17, 2017 | Project value $475,001 | 1 partners | $200,001 from BioCanRx

 

Eligible cancers: all cancers with tumours
Keywords: adoptive T cell therapy, anti-CD19 CAR-T

 

 
 

 
 

Infected Cell Vaccines in the Treatment of Acute Leukemia: Laying the Groundwork for a Clinical Trial

 

Dr. Natasha Kekre, The Ottawa Hospital Research Institute, University of Ottawa
Approved October 14, 2016 | Project value $275,860 | 6 partners | $155,888 from BioCanRx

 

Eligible cancers: acute leukemia
Keywords: Maraba MG1, oncolytic vaccine

 

 
 

 
 

Targeted radioligand (tRL) and checkpoint blockade for metastatic castrate resistant prostate cancer

 

Dr. Julian J. Lum, BC Cancer Agency, University of Victoria
Approved January 17, 2017 | Project value $399,996 | 4 partners | $199,996 from BioCanRx

 

Eligible cancers: metastatic castrate resistant prostate cancer (mCRPC)
Keywords: Check-point blockades, local radiation, mCPC10

 

 
 

 
 

Pre-clinical validation of anti-SIRPα antibodies anti-tumor efficacy through immuno-modulation of macrophages

 

Dr. Sachdev Sidhu, University Health Network, University of Toronto
Approved January 17, 2017 | Project value $304,681 | 1 partner | $200,000 from BioCanRx

 

Eligible cancers: all cancers
Keywords: Therapeutic Antibodies, T cells, CD47-SIRPα

 

 
 

 
 

Bispecific T-cell engager antibodies targeting CD133+ brain tumor-initiating cells: A Novel Immunotherapy for Recurrent Glioblastoma

 

Dr. Sheila Singh, McMaster University
Approved October 14, 2016 | Project value $465,000 | 3 partners | $200,000 from BioCanRx

 

Eligible cancers: brain cancer (recurrent glioblastoma)
Keywords: bispecific T cell engager antibodies (BiTEs), CD133/CD3

 

 
 

 
 

Recombinant TCRs and peptide-MHC antibodies to target KRAS hotspot mutations in pancreatic cancer

 

Dr. Simon Turcotte, Université de Montréal
Approved October 14, 2016 | Project value $266,968 | 5 partners | $133,111 from BioCanRx

 

Eligible cancers: pancreatic cancer
Keywords: adoptive cell transfer, KRASG12x peptide-MHC, engineered T cell

 

 
 

 
 

DEVELOPMENT OF AN ONCOLYTIC VACCINE FOR BRAIN CANCER

 

Dr. David Stojdl, CHEO Research Institute, uOttawa
Approved June 10, 2015 | Project value $401,878 | 1 partner | $200,239 from BioCanRx

 

Eligible cancers: glioblastoma multiforme (GBM)
Keywords: oncolytic virus, oncolytic vaccine, Farmington virus, Maraba oncolytic virus, FMT, MRB-LCMVgp, CMV pp65/IE1 antigen

 

 
 

 
 

DEVELOPMENT OF A BIOREACTOR SYSTEM TO AUTOMATE T-CELL MANUFACTURING

 

Drs. Jonathan Bramson and Raja Ghosh, McMaster University
Approved June 10, 2015 | Project value $364,726 | 4 partners | $107,500 from BioCanRx

 

Impact: greatly increase the number of clinical sites able to perform cancer cell therapies; dramatically reduce the cost of manufacturing therapeutic cells for cancer treatment
Keywords: T-cell, cell therapy, GMP, bioreactor, cell manufacturing, biotechnology

 

 
 

 
 

CREATING T-CELL RECEPTORS THAT REACT TO SPECIFIC TUMOUR ANTIGENS FOR IMPROVED ADOPTIVE T-CELL THERAPY

 

Dr. Naoto Hirano, Princess Margaret Cancer Centre, University Health Network
Approved June 10, 2015 | Project value $475,001 | 1 partner | $200,001 from BioCanRx

 

Eligible cancers: anal, bladder, breast, cervical, colon, esophageal, kidney, liver, lung, melanoma, mouth, ovarian, pancreatic, prostate, stomach, testicular, uterine
Keywords: Adoptive T-cell therapy, T Cell receptors, TCR, MAGE-A3, NY-ESO-1